Stock comparison
IDEXX Laboratories
Penumbra
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
PEN
Penumbra
Market cap
$12.93B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | PEN | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 57C | IDXX |
| Benjamin Graham | 80A | 72D | IDXX |
| Philip Fisher | 75B | 78C | PEN |
| Peter Lynch | 71B | 54C | IDXX |
| Joel Greenblatt | 83C | 52D | IDXX |
| Charlie Munger | 87A | 51D | IDXX |
| Terry Smith | 84A | 54D | IDXX |
Side-by-side metrics
| Metric | IDXX | PEN |
|---|---|---|
| Market cap | $44.12B | $12.93B |
| P/E (TTM) | 39.0x | 74.0x |
| EV/EBIT | 31.6x | 66.9x |
| ROIC (TTM) | 40.66% | 9.26% |
| Gross margin | 62.05% | 67.38% |
| Net margin | 24.63% | 11.76% |
| Revenue CAGR 5y | 7.56% | 17.06% |
| EPS CAGR 5y | 10.79% | 139.03% |
| Debt / Equity | 0.7x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- ROIC (TTM)40.66%vs 9.26%+77%
- Market cap$44.12Bvs $12.93B+71%
- EV/EBIT31.6xvs 66.9x+53%
- Net margin24.63%vs 11.76%+52%
PEN leads on
- EPS CAGR 5y139.03%vs 10.79%+92%
- Debt / Equity0.1xvs 0.7x+79%
- Revenue CAGR 5y17.06%vs 7.56%+56%
- Gross margin67.38%vs 62.05%+8%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.